Glaukos Corporation (GKOS) saw its stock price surge 14.15% in after-hours trading on Wednesday, following the release of its impressive third-quarter results and optimistic future guidance. The ophthalmic medical technology company significantly outperformed market expectations, demonstrating robust growth and improved profitability.

For the third quarter, Glaukos reported adjusted earnings per share of -$0.16, beating the analysts' estimate of -$0.26. The company achieved record net sales of $133.5 million, a 38% year-over-year increase, surpassing the expected $122.5 million. Notably, U.S. glaucoma sales showed exceptional strength, growing 57% year-over-year to $80.8 million. The company's gross margin improved to approximately 78%, with a non-GAAP gross margin of about 84%.

Investors were particularly enthused by Glaukos's forward-looking projections. The company raised its 2025 net sales guidance to a range of $490 million to $495 million, up from the previous estimate of $480 million to $486 million. Moreover, Glaukos introduced its preliminary net sales outlook for 2026, forecasting sales between $600 million and $620 million, signaling confidence in sustained long-term growth. This combination of strong current performance and optimistic future outlook appears to be the primary driver behind the significant after-hours stock price increase.